Science

Guilherme Nader Marta: The current role of anthracyclines in early breast cancer treatment

Guilherme Nader Marta/X

Feb 9, 2025, 15:31

Guilherme Nader Marta: The current role of anthracyclines in early breast cancer treatment

Guilherme Nader Marta, Advanced Clinical Fellow at Dana-Farber Cancer Institute, shared an article on X:

“If you’re interested in the topic, don’t miss our full review on the current role of anthracyclines in early breast cancer treatment.

We analyze efficacy, toxicity & pt selection, including data recently presented on the predictive value of Oncotype & Mamma Print.”

“Honored to share our article in the NEJM Breast Cancer Update, discussing two perspectives on anthracycline use in breast cancer—a long-debated topic that remains highly relevant today Grateful to co-author this work with Prof. Martine Piccart.”

Guilherme Nader Marta: The current role of anthracyclines in early breast cancer treatment

Redefining the role of anthracyclines in early breast cancer treatment.

Authors: Guilherme Nader-Marta, et al.

Guilherme Nader Marta: The current role of anthracyclines in early breast cancer treatment

Anthracyclines Breast Cancer cancer Dana-Farber Cancer Institute fight against cancer Global fight against cancer Guilherme Nader Marta OncoDaily Oncology Oncotype

Douglas Flora: Fighting Cancer with Heart

Eric Small: Deeply Honored to Step Into the Role of 2025-26 ASCO President

Cyril Konto: I Trademarked The Word ‘Multispecific’ The Day I Arrived

Levi Garraway: Transforming Oncology Through Precision, Resilience And Heart

20 Posts Not to Miss from ASCO 2025